Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC

Immune-checkpoint inhibitors (ICIs) have showed unprecedent efficacy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). However, not all patients manifest clinical benefit due to th...

Source: Journal of Experimental and Clinical Cancer Research - March 15, 2024 Category: Cancer & Oncology Authors: Diego de Miguel ‑Perez, Murat Ak, Priyadarshini Mamindla, Alessandro Russo, Serafettin Zenkin, Nursima Ak, Vishal Peddagangireddy, Luis Lara‑Mejia, Muthukumar Gunasekaran, Andres F. Cardona, Aung Naing, Fred R. Hirsch, Oscar Arrieta, Rivka R. Colen an Tags: Commentary Source Type: research